The oncology franchise is the engine, with expanding capacity and Nivian adding scale. But the latest print cooled, and at this rich price the market already banks it all.
Overall read
5.9/10
Priced ahead of it
The three reads · this quarter
The oncology franchise is the engine, with expanding capacity and Nivian adding scale. But the latest print cooled, and at this rich price the market already banks it all.
Overall read
5.9/10
Priced ahead of it
The three reads · this quarter
The standing reads · change less often
Moat
Slim edge
Key variables
5 tracked
lead: Capacity utilizationCapacity utilization has remained moderate across oral and injectable lines, with Lyo running near full. The headroom to generate INR700-800 Cr revenue without major capex indicates significant operating leverage, but also suggests that near-term growth is not
Walk the talk
Not enough data
as of Q4 FY26Nivian acquisition (Apr 2026) adds INR45-46 Cr revenue with 30% CAGR; cross-synergies in procurement and distribution.
Latest · newest first
No material exchange filings in the last 60 days. Latest scored quarter: Q4FY26.
Open the Exchange Desk0 of 1 guidance items delivered on time
Where it sits